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ABSTRACT
Objective Human leucocyte antigen (HLA)-B27 and
endoplasmic reticulum aminopeptidase 1 (ERAP1) are
strongly associated with ankylosing spondylitis (AS).
ERAP1 is a key aminopeptidase in HLA class I
presentation and can potentially alter surface expression
of HLA-B27 free heavy chains (FHCs). We studied the
effects of ERAP1 silencing/inhibition/variations on HLA-
B27 FHC expression and Th17 responses in AS.
Methods Flow cytometry was used to measure surface
expression of HLA class I in peripheral blood
mononuclear cells (PBMCs) from patients with AS
carrying different ERAP1 genotypes (rs2287987,
rs30187 and rs27044) and in ERAP1-silenced/inhibited/
mutated HLA-B27-expressing antigen presenting cells
(APCs). ERAP1-silenced/inhibited APCs were cocultured
with KIR3DL2CD3ε-reporter cells or AS CD4+ T cells.
Th17 responses of AS CD4+ T cells were measured by
interleukin (IL)-17A ELISA and Th17 intracellular cytokine
staining. FHC cell surface expression and Th17 responses
were also measured in AS PBMCs following ERAP1
inhibition.
Results The AS-protective ERAP1 variants, K528R and
Q730E, were associated with reduced surface FHC
expression by monocytes from patients with AS and
HLA-B27-expressing APCs. ERAP1 silencing or inhibition
in APCs downregulated HLA-B27 FHC surface
expression, reduced IL-2 production by KIR3DL2CD3ε-
reporter cells and suppressed the Th17 expansion and
IL-17A secretion by AS CD4+ T cells. ERAP1 inhibition
of AS PBMCs reduced HLA class I FHC surface
expression by monocytes and B cells, and suppressed
Th17 expansion.
Conclusions ERAP1 activity determines surface
expression of HLA-B27 FHCs and potentially promotes
Th17 responses in AS through binding of HLA-B27 FHCs
to KIR3DL2. Our data suggest that ERAP1 inhibition has
potential for AS treatment.
INTRODUCTION
Ankylosing spondylitis (AS) is the prototype of the
spondyloarthritis (SpA), a group of closely related
chronic inﬂammatory diseases sharing clinical
symptoms and strong genetic association with the
human leucocyte antigen (HLA)-B27. The mechan-
ism by which HLA-B27 confers disease susceptibil-
ity remains unclear. The canonical function of
HLA-B27 is to form heterotrimers with
β2-microglobulin (β2m) and antigenic peptides in
the endoplasmic reticulum (ER), which then egress
to the cell surface for CD8+ T cell recognition.
However, lack of CD8+ T cells does not prevent
disease in the HLA-B27-trangenic rat model of SpA,
arguing against a primary role of CD8+ Tcell activa-
tion by classical HLA-B27 in SpA.1 2 We and others
have shown the presence of HLA-B27 β2m-free
heavy chains (FHCs) on the surface of peripheral
blood mononuclear cells (PBMCs) from patients with
SpA and HLA-B27-trangenic rats.3–6 The biological
function of HLA-B27 FHCs is supported by its
superior binding afﬁnity, in comparison to classical
HLA-B27, to the immunoregulatory receptors killer
cell immunoglobulin-like receptor 3DL2 (KIR3DL2)
and leucocyte immunoglobulin-like receptor B2
(LILRB2).7 8 Importantly, binding of HLA-B27
FHCs to KIR3DL2 expressed by CD4+ T cells has
been shown to promote the survival and proliferation
of Th17 cells in AS.9 10
The strong genetic association of AS with ER
aminopeptidase 1 (ERAP1) has been reported by
multiple studies in different ethnic groups.11–17
Five AS-associated ERAP1 single nucleotide poly-
morphisms (SNPs) were found: rs30187 (T/C,
K528R), rs27044 (G/C, Q730E), rs2287987 (T/C,
M349V), rs10050860 (C/T, D575N), rs17482078
(C/T, R725Q) (risk alleles and their corresponding
amino acids are underlined). ERAP1 locates in the
ER and trims peptides to optimal length (usually
8–10 amino acids) before their binding to major
histocompatibility complex (MHC) class I mole-
cules. Strikingly, ERAP1 polymorphisms only affect
AS risk in HLA-B27-positive individuals, implying
that ERAP1 contributes to AS pathogenesis by alter-
ing HLA-B27 function.17 Indeed, ERAP1 silencing
or polymorphisms has been shown to alter the
length and sequence of HLA-B27-bound pep-
tides.18 19 A recent study shows that AS-associated
ERAP1 polymorphisms do not alter ER stress in
patients with AS, arguing against the unfolded
protein response theory.20 We hypothesised that
ERAP1 might contribute to AS pathogenesis
through altering cell surface HLA-B27 FHC
expression.
To test this hypothesis, we studied the effect of
ERAP1 silencing, inhibition and polymorphic
Open Access
Scan to access more
free content
916 Chen L, et al. Ann Rheum Dis 2016;75:916–923. doi:10.1136/annrheumdis-2014-206996
Basic and translational research
group.bmj.com on June 13, 2017 - Published by http://ard.bmj.com/Downloaded from 
variation on HLA-B27 FHC expression and Th17 function.
Protective ERAP1 polymorphisms are associated with reduced
HLA FHC expression in monocytes of patients with AS and
HLA-B27-expressing antigen presenting cells (APCs). ERAP1
silencing or inhibition of APCs reduces HLA-B27 FHC expres-
sion, KIR3DL2 stimulation and Th17 responses. Finally, ERAP1
inhibition reduces HLA class I FHC expression and Th17
expansion in PBMCs from patients with AS.
MATERIALS AND METHOD
Patients with AS
Heparinised venous blood was obtained from 56 HLA-B27-
positive patients with AS fulﬁlling the modiﬁed New York
criteria. Patient demographics are shown (see online
supplementary table S1). Patients were assessed for disease activ-
ity using Bath AS Disease Activity Index (BASDAI), functional
capacity using Bath AS Functional Index (BASFI) and spinal
mobility using Bath AS Metrology Index (BASMI).
Genotyping
DNA was prepared from peripheral blood cells using PureLink
Genomic DNA Mini Kit (Life Technologies, UK). Three SNPs
in the ERAP1 gene previously reported to be associated with
AS, rs2287987 (T/C, M349V), rs30187 (T/C, K528R) and
rs27044 (G/C, Q730E) were genotyped using functionally
tested TaqMan Assays (Applied Biosystems, UK). Two additional
AS-associated SNPs, rs10050860 (C/T, D575N), rs17482078
(C/T, R725Q), were not genotyped in this study. However, we
found that they are in strong link disequilibrium with
rs2287987 (T/C, M349V) in a set of 60 patients with AS
(rs10050860: r2=1, D0=1; rs17482078: r2=0.956, D0=1, data
not shown). This strong linkage was also found to be present in
the general population using a public SNPs link disequilibrium
calculation tool (rs10050860: r2=0.92, D0=1; rs17482078:
r2=0.959, D0=1, SNP Annotation and Proxy Search, Broad
Institute of Massachusetts Institute of Technology and Harvard).
Cell lines
As described previously, HeLa.B27, C1R.B27 and mouse endo-
plasmic reticulum aminopeptidase associated with antigen
processing (ERAAP)−/− ﬁbroblasts (ERAAP−/− mFib.B27) were
transfected to express HLA- HLA-B*27:05.18 21 See online
supplementary methods for cell culturing conditions.
ERAP1 stable silencing and inhibition
As described previously, lentiviral ERAP1-shRNA was used to
stably silence endogenous ERAP1 expression by HeLa.B27 and
C1R.B27 cells.18 In the current study, DG013A was initially
titrated at the concentration of 10 nM, 100 nM and 1000 nM.
1000 nM of DG013A was then used for ERAP1 inhibition.
Construction and transfection of shRNA-resistant ERAP1
plasmids
See online supplementary methods.
Isolation of PBMCs and CD4+ T cells
See online supplementary methods.
Flow cytometry
PBMCs were blocked with Fc receptor blocking reagent
(Miltenyi Biotec), stained for HLA class I FHCs with the
HC-10 (IgG2a) and classical HLA-B27 complexes with ME-1
(IgG1). An APC-conjugated antimouse IgG antibody (Santa
Cruz, USA) was used to detect HC-10 and ME-1. Monocyte, B
cell and T cell were stained by CD14-PE (Miltenyi Biotec),
CD19-Paciﬁc Blue and CD3- PerCP-Cy5.5 (BioLegend, USA),
respectively. Dead cells were excluded using Fixable Viability
Dye eFluor 780 (Ebioscience, UK). In order to ensure unbiased
comparison of FHC expression, all PBMC samples were stained
and analysed in a single batch.
HeLa.B27, C1R.B27 and mFib.B27 cells were stained by
HC-10 and ME-1 antibodies followed by APC-conjugated anti-
mouse IgG antibody. Dead cells were excluded using LIVE/
DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies).
BD LSRFortessa and Diva software were used. The latter con-
verts channel value into ﬂuorescence intensity using a logarith-
mic algorithm, therefore geometrical mean ﬂuorescence
intensity was used to quantify the intensity of HC-10 and ME-1
staining.
Intracellular cytokine staining of Th17/Th1 cells was carried
out using BD Cytoﬁx/Cytoperm kit (BD Bioscience, UK). Cells
were stimulated with 100 ng/mL phorbol 12-myristate
13-acetate (PMA) (Sigma) and 1 mg/mL Ionomycin (Sigma) for
4 h in the presence of Golgi STOP and Golgi plug. After surface
staining using CD3-BV605, CD4-APC and CD8-BV510 anti-
bodies (Biolegend), cells were ﬁxed and permeabilised, stained
with interleukin (IL)-17A-FITC (Ebioscience) and interferon
(IFN)-γ-AF700 (Biolegend). Dead cells were excluded using
Fixable Viability Dye eFluor 780 (Ebioscience).
KIR3DL2CD3ε reporter cell assay
The KIR3DL2CD3ε reporter cells secreting IL-2 have been pre-
viously described.9 10 See online supplementary methods for
details.
Coculture of CD4+ T cells with APCs
About 100 000 CD4+ T cells were cocultured with 5000 HeLa.
B27/C1R.B27 cells in 50 mL/200 mL R10 supplemented with
1 pg/mL staphylococcal enterotoxin B (SEB) and 50 ng/mL IL-2.
Supernatants were harvested on day 3 for IL-17A ELISA
(Ebioscience) cells stained on day 6 for Th17.
ERAP1 inhibition of AS PBMCs
About 100 000 AS PBMCs were cultured overnight in 100 mL
R10 with/without the addition of DG013A (1000 nM), stained
for classical HLA-B27 and FHC surface expression. For Th17
responses, 500 000 AS PBMCs were cultured in 200 mL R10
with the addition of SEB (1 pg/mL), IL-2 (50 IU/mL) and
DG013A (1000 nM) for 6 days. Supernatants were collected on
day 3 for IL-17A ELISA, cells stained on day 6 for Th17.
DG013Awas replenished daily, SEB and IL-2 on day 3.
Statistics
Results are expressed as mean and SE of mean (ﬁgures 1, 4C, D
and 5) or SD (other ﬁgures). The statistical signiﬁcance of differ-
ences between means was assessed using Mann-Whitney test
(ﬁgure 1), unpaired two-tailed t test (ﬁgures 2 and 4A, B), one
way Analysis of variance (ANOVA) (ﬁgure 3) or paired two-
tailed t test (ﬁgures 4C, D and 5). A p value <0.05 was consid-
ered statistically signiﬁcant.
RESULTS
Protective ERAP1 variants are associated with reduced HLA
class I FHC expression by AS monocytes
We ﬁrst investigated the effect of ERAP1 polymorphisms on
FHC expression in PBMCs from HLA-B27-positve patients with
AS. Three AS-associated ERAP1 SNPs were studied: rs30187
(T/C, K528R), rs27044 (G/C, Q730E) and rs2287987 (T/C,
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M349V). Risk alleles and their corresponding amino acids are
underlined. No signiﬁcant difference in the age, BASDAI,
BASFI, BASMI was present between genotypical groups (see
online supplementary table S1). Figure 1 shows that monocytes
from patients carrying AS protective alleles of rs30187 or
rs27044 (528R or 730E) express signiﬁcantly lower absolute
(HC-10) and relative (HC-10/ME-1 ratio) levels of HLA class I
FHCs. A similar but non-signiﬁcant trend was seen in B cells
and T cells. No signiﬁcant difference was found between
patients carrying risk and protective alleles of rs2287987 (see
online supplementary ﬁgure S1).
ERAP1 silencing or inhibition reduces HLA-B27 FHC
expression
The K528R and Q730E ERAP1 variants, corresponding to pro-
tective alleles of rs30187 and rs27044 respectively, have been
shown to reduce enzyme activity.17 18 22–24 We therefore
explored the effects of ERAP1 silencing on HLA-B27 FHCs
expression. Lentiviral ERAP1-shRNAwas used to stably suppress
the expression of endogenous ERAP1 by HeLa.B27 and C1R.
B27 cells (85–90% suppression, see online supplementary
ﬁgure S2). As shown in ﬁgure 2A–D, ERAP1 silencing led to a
30–40% reduction of HLA-B27 FHC expression by HeLa.B27
and C1R.B27 cells. Unlike the untransfected C1R cells, which
express low levels of MHC class I molecules and bind only
weakly to HC-10 antibody, untransfected HeLa cells could be
stained by HC-10 (see online supplementary ﬁgure S3). In
order to exclude the possibility that the reduced HC-10 staining
following ERAP1-silencing in HeLa.B27 cells was due to down-
regulation of other MHC class I, we silenced ERAP1 in untrans-
fected HeLa. This did not decrease HC-10 staining (see online
supplementary ﬁgure S4). In addition to ERAP1 silencing, we
also examined the effect of ERAP1 inhibition on HLA-B27 FHC
expression using a recently identiﬁed compound, DG013A.25
DG013A is a phosphinic pseudopeptide that binds to the catalytic
site of ERAP1. It also inhibits ERAP2 and leucyl/cystinyl amino-
peptidase (LNPEP) (both AS-associated).25 26 Figure 2E–H show
that DG013A decreased FHC expression by HeLa.B27 and C1R.
B27 cells in a dose-dependent manner, without reducing ME-1
levels. Moreover, ERAP1 silencing or inhibition also signiﬁcantly
reduced the staining by HD-6, an antibody raised against
HLA-B27 homodimers (see online supplementary ﬁgure S5).10 27
Expression of wild type (WT)-ERAP1, but not AS protective
variants, in ERAP1-silenced HeLa.B27 and ERAAP−/− mFib.
B27 cells increases FHC expression
To further conﬁrm the role of ERAP1 in determining HLA-B27
FHC expression, we next introduced WT-ERAP1 into
ERAP1-silenced HeLa.B27 and ERAAP−/− mFib.B27 cells.
ShRNA-resistant ERAP1 plasmids encoding WT and variants
were constructed by introducing multiple synonymous mutations
in the shRNA-targeting sequence (see online supplementary
ﬁgure S6A). Online supplementary ﬁgure S6B shows that ERAP1
was successfully expressed in ERAP1-silenced HeLa.B27 cells
using ShRNA-resistant ERAP1 plasmids but not unmutated
WT-ERAP1. Expression of WT-ERAP1 signiﬁcantly upregulated
Figure 1 Patients with ankylosing spondylitis (AS) carrying protective endoplasmic reticulum aminopeptidase 1 variants, K528R or Q730E, have
lower monocyte human leucocyte antigen (HLA) class I free heavy chain (FHC) expression. HC-10 antibody (HLA class I FHCs) and ME-1 antibody
(classical β2m-associated HLA-B27, B7, B42, B67, B73 and Bw22) staining of CD14+ monocyte, CD19+ B cell and CD3+ T cell from peripheral
blood mononuclear cells in patients with AS are shown. HC-10 staining, ME-1 staining and HC-10/ME-1 are compared between patients with AS
with different genotypes of rs30187 (TT, CT, CC) in (A) and rs27044 (GG, CG, CC) in (B). Risk alleles and corresponding amino acids are underlined.
Results are expressed as mean and SE of mean, p value was determined by Mann-Whitney test (*p<0.05, **p<0.01). Insufﬁcient HLA-B27+ healthy
controls were available for comparison.
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the expression of HLA-B27 FHCs in ERAP1-silenced HeLa.B27
(ﬁgure 3A, B) and ERAAP−/− mFib.B27 cells (ﬁgure 3C, D) (see
online supplementary ﬁgure S7 for representative stains).
Transfection using WT-ERAP1 without synonymous mutations
did not affect the expression of surface FHCs, further conﬁrming
that the increase of FHC expression is due to introduction of
ERAP1 (see online supplementary ﬁgure S6C).
Figure 3 also shows that, in ERAP1-silenced HeLa.B27 and
ERAAP−/− mFib.B27 cells, the K528R, Q730E and K528R/
Q730E variants did not upregulate FHCs. The double variant
was studied because of the genetic linkage between K528R and
Q730E (r2=0.734, D0=1, SNP Annotation and Proxy Search).
Notably, no signiﬁcant difference in ERAP1 expression levels
was observed between ERAP1 variants (ﬁgure 3A, C).
Figure 2 Endoplasmic reticulum
aminopeptidase 1 (ERAP1) silencing or
inhibition reduces surface human
leucocyte antigen (HLA)-B27 free
heavy chain (FHC) expression by HeLa.
B27 or C1R.B27 cells. The expression
of HLA-B27 FHCs (HC-10 antibody)
and classical HLA-B27 complexes
(ME-1 antibody) surface expression are
compared between ctr-shRNA and
ERAP1-shRNA-transduced HeLa.B27
cells (A) and C1R.B27 cells (C).
Summaries are shown in (B) and (D).
Neither the IgG2a (isotype control for
HC-10, data shown here) nor IgG1
(isotype control for ME-1, data not
shown) stains HeLa.B27 and C1R.B27
cells. Representative stains of HeLa.
B27 cells (E) and C1R.B27 cells (G)
treated with 1000 nM DG013 are
shown. Summaries of DG013A titration
(0 nM, 10 nM, 100 nM, 1000 nM) on
HeLa.B27 cells and C1R.B27 cells are
shown in (F) and (H). All experiments
were repeated three times. Results are
expressed as mean and SD. p Value
was determined using unpaired
two-tailed t test (*p<0.05, **p<0.01).
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ERAP1 silencing or inhibition of HLA-B27-expressing APCs
reduces ligation of KIR3DL2 by HLA-B27 FHCs and Th17
responses from AS CD4+ T cells
The best characterised function of HLA-B27 FHCs is their inter-
action with KIR3DL2. HLA-B27 FHCs bind to KIR3DL2 more
strongly than classical HLA-B27 molecules, and stimulate the
survival, proliferation and IL-17A production of KIR3DL2+
CD4+ T cells from patients with AS.9 We therefore asked if
ERAP1 suppression/inhibition affects functional recognition of
HLA-B27-expressing APCs by KIR3DL2. When HeLa.B27 or
C1R.B27 cells were cocultured with KIR3DL2CD3ε reporter
cells, ERAP1 silencing (ﬁgure 4A) or inhibition (ﬁgure 4B)
reduced the activation of this receptor (reﬂected by IL-2 produc-
tion). Blocking using either HC-10 or DX31 (speciﬁc for
KIR3DL2) antibodies reduced IL-2 to basal levels, conﬁrming
that IL-2 secretion in this assay is due to the interaction of
HLA-B27 FHCs and KIR3DL2.
We next investigated whether ERAP1 silencing or inhibition
of APCs affected Th17 expansion when the APCs were
cocultured with CD4+ T cells from patients with AS.
Differentiation of Th17 cells and secretion of IL-17A were
reduced when ERAP1 of APCs was silenced (ﬁgure 4C) or
inhibited (ﬁgure 4D).
ERAP1 inhibition reduces surface HLA class I FHCs and Th17
cell frequency of PBMCs in patients with AS
We lastly examined the potential of ERAP1 inhibition to modu-
late FHC expression and Th17 expansion in PBMCs from
patients with AS. Figure 5A shows that overnight treatment
of PBMCs using DG013A decreased HLA class I FHC
expression by monocytes and B cells. No effect was observed
on T cells (see online supplementary ﬁgure S8A). ERAP1
inhibition also decreased the Th17 expansion from AS
PBMCs after 6 days (ﬁgure 5B), without signiﬁcantly redu-
cing the frequency of IFN-γ-producing Th1 cells (see online
supplementary ﬁgure S8B).
DISCUSSION
In this study we show that ERAP1 plays an important role in
determining the expression levels of cell surface HLA-B27
FHCs. Genetic silencing and chemical inhibition of ERAP1 led
to similar reduction of HLA-B27 FHC expression, indicating
that the effect is speciﬁc. By contrast, the introduction of wild-
type ERAP1 into ERAP1-silenced or ERAAP-knockout cells
increased FHC expression. Increased monocyte FHC expression
in patients with AS has been described previously,4 6 but in
these studies ERAP1 was not genotyped. We show for the ﬁrst
time that patients with AS carrying protective allelic variants of
ERAP1, 528R and 730E, have reduced monocyte HLA class I
FHC expression. Our result provides an immunological explan-
ation for the low AS risk conferred by these two ERAP1 var-
iants. The fact that the 528R and 730E variants, similar to
ERAP1 silencing and inhibition, have downregulating effect
on HLA-B27 FHCs suggests that they are effectively
loss-of-function variants. This is supported by our ﬁnding that
introduction into ERAP1-silenced or ERAAP−/− cell lines of
these variants, singly or in combination, does not upregulate
HLA-B27 FHC expression. This is also in accordance with pre-
vious in vitro studies using synthetic peptides and cell-based
HLA-B27 peptidome studies.17 19 22–24 28 We did not observe a
Figure 3 Wild type endoplasmic reticulum aminopeptidase 1 (ERAP1), but not the protective variants K528R or Q730E, increases cell surface
human leucocyte antigen (HLA)-B27 free heavy chain (FHC) expression. WT-ERAP1 and protective ERAP1 variants (K528R, Q730E, K528R/Q730E)
were transiently expressed in ERAP1-silenced HeLa.B27 cells and ERAAP-knockout mFib.B27 cells. (A and C) Western blot showing that ERAP1
variants have been expressed at similar levels. The expression of HLA-B27 FHCs (HC-10 antibody) and classical HLA-B27 complexes (ME-1 antibody)
surface expression are compared between HeLa.B27 cells (B) and mFib.B27 cells (D) expressing different ERAP1 variants. Both experiments were
repeated three times. Results are expressed as mean and SD. p Value was determined using one way ANOVA (**p<0.01, ***p<0.001).
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signiﬁcant effect for the 349V variant, noting that its genetic
association with AS is much weaker.13 17 Notably, although all
patients with AS in this study were HLA-B27-positive, the con-
tribution of other HLA class I molecules to PBMC FHC expres-
sion could not be excluded. Our results differ in some aspects
from the ﬁndings of Haroon et al,29 which found that 730E
increased monocyte FHC levels in patients with AS and 528R
had little effect. They also found that ERAP1 siRNA silencing of
C1R.B27 cells did not alter cell surface FHC expression. In the
current study we have achieved more efﬁcient and stable ERAP1
silencing using shRNA, and studied the HeLa.B27 cells in add-
ition to C1R.B27 cells. Moreover, in addition to monocytes of
patients with AS , we showed the reduction of FHC expression
by the 528R and 730E mutations in ERAP1-reconstituted cell
lines. Finally, we also studied the effect of ERAP1 inhibition on
FHC expression in cell lines and AS PBMCs.
We also show that ERAP1 silencing or inhibition of APCs has
functional effects on KIR3DL2 stimulation and Th17 cell
expansion. Silencing or inhibition of HeLa.B27 and C1R.B27
cells reduced recognition by a KIR3DL2 reporter cell line by
approximately 30%, similar to the amount of reduction in FHC
surface expression. When CD4+ T cells in patients with AS were
cultured with APCs, ERAP1 silencing or inhibition reduced Th17
expansion and IL-17A secretion. These ﬁnding suggest that
ERAP1 inhibition might have therapeutic beneﬁt in AS.
Our ﬁndings might at ﬁrst appear to be difﬁcult to reconcile
with our previous ﬁnding that ERAP1 silencing increases the
length of peptides (11–13 polymers) bound to HLA-B27.18
However, these long peptides stabilised classical surface
HLA-B27 molecules just as well as 9 nonamer HLA-B27 epi-
topes in T2 HLA-B27 stabilisation assays,18 suggesting that
HLA-B27 complexes loaded with longer peptide ligands are in
Figure 4 Endoplasmic reticulum
aminopeptidase 1 (ERAP1) silencing or
inhibition of human leucocyte antigen
(HLA)-B27-expressing antigen
presenting cells (APCs) reduces
interleukin (IL)-2 production by
KIR3DL2CD3ε-expressing reporter cells,
and inhibits Th17 cell expansion and
IL-17A production by CD4+ T cells
from patients with ankylosing
spondylitis (AS). The effect of ERAP1
silencing (A) and inhibition (B) in APCs
on IL-2 production by
KIR3DL2CD3ε-expressing reporter cells
are shown. IL-2 ELISA was used to
measure the ligation of KIR3DL2 by
HLA-B27 free heavy chains. HC-10 or
DX31 blocked the production of IL-2,
but not isotype control antibody. The
effect of ERAP1 silencing (C) and
inhibition (D) in APCs on Th17
expansion and IL-17A production are
also shown. HLA-B27-expressing APCs
were cocultured with CD4+ T cells
from patients with AS (n=5) at the
presence of 50 U/mL IL-2 and 1 pg/mL
staphylococcal enterotoxin
B. Supernatant was collected for
IL-17A ELISA at day 3, cells were
harvested for Th17 cell staining at day
6. Experiments in (A and B) were
repeated three times. Results are
expressed as mean and SD (A and B)
or SE (C and D). p Value was
determined using unpaired two-tailed t
test in (A and B) and paired two-tailed
t test in (C and D) (*p<0.05,
**p<0.01).
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fact as stable as those carrying 9–10 polymer epitopes. These
longer peptides are potentially optimal ligands for classical
HLA-B27 complex formation, and are enriched when ERAP1 is
silenced. Thus suppression of ERAP1 might increase the overall
pool of high afﬁnity peptide ligands available for binding to
HLA-B27. This could explain our ﬁnding that surface HLA-B27
FHC expression is reduced by ERAP1 silencing or inhibition.
Therefore, ERAP1 might contribute to disease by actively destroy-
ing HLA-B27-binding peptide epitopes. Indeed, WT-ERAP1 has
been shown to more rapidly destroy multiple HLA-B27-destined
peptides than loss-of-function ERAP1 variants.28 Recently pub-
lished data has suggested that ERAP1 allotypes/haplotypes with
abnormally high or low peptide trimming activity may predis-
pose to AS by limiting the supply of optimal peptides to
HLA-B27 and therefore adversely affecting its conformational
stability.30 Alternatively, ERAP1 may contribute to a chaperone
activity within the ER resulting in accelerated egress of
HLA-B27 FHCs and classical HLA-B27 molecules. As shown
in ﬁgure 2A–D, in addition to reducing HLA-B27 FHC surface
expression, ERAP1 silencing of APCs has a trend, although not
signiﬁcant, to downregulate surface classical HLA-B27.
Notably DG013A is a potent inhibitor for ERAP2 and
LNPEP as well as ERAP1.25 While we cannot exclude effects on
these aminopeptidases, it is important to note that ERAP2 and
LNPEP are also associated with AS.26 Any off-target effect could
thus potentially be beneﬁcial in AS treatment. Moreover, the
reduction of HLA-B27 FHC levels by DG013A was not seen in
221.B27 cells (data not shown) and reduction of PBMC HLA
class I FHC expression was not seen for two out of nine patients
with AS (ﬁgure 5A). ERAP1 inhibitors with higher selectivity
and/or potency are worth investigating.
Overall, our data show that ERAP1 plays a critical role in
determining levels of HLA-B27 FHC expression and Th17
responses in AS. ERAP1 silencing or inhibition reduces
HLA-B27 FHC expression. Disease-protective ERAP1 alleles
are associated with lower FHC expression levels in reconsti-
tuted cell lines and patients with AS. We also provide the ﬁrst
evidence that ERAP1 inhibition may suppress Th17 response
in AS. Therefore, ERAP1 inhibition could potentially be used
for therapy in AS.
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Figure 5 Endoplasmic reticulum
aminopeptidase 1 inhibition reduces
peripheral blood mononuclear cell
(PBMC) surface human leucocyte
antigen (HLA) class I free heavy chain
(FHC) expression and Th17 expansion
in patients with ankylosing spondylitis
(AS). (A) PBMCs from patients with AS
(n=9) were cultured with 1000 nM
DG013A for 16 h. HLA class I FHCs
(HC-10 antibody) and classical
HLA-B27 (ME-1 antibody) surface
expression by CD14+ monocyte, CD19
+ B cell from PBMCs in patients with
AS are shown. (B) PBMCs from
patients with AS (n=9) were cultured
with 1000 nM DG013A for 6 days in
the presence of 50 U/mL IL-2, 1 pg/mL
staphylococcal enterotoxin
B. Supernatant was collected for
IL-17A ELISA at day 3, cells were
harvested for Th1 and Th17 cell
staining at day 6. For both
experiments, patients with AS with
high basal HC-10 expression were
chosen. Results are expressed as mean
and SE. p Value was determined using
paired two-tailed t test (*p<0.05,
**p<0.01).
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